Drugs / PEG-IFN-SA
PEG-IFN-SA
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01605513 | Jun 2011 → Dec 2013 | hepatitis C virus infection | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01908335 | Oct 2012 → Aug 2013 | chronic hepatitis C virus infection | Beijing Kawin Technology Share-Holding Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01903278 | Jun 2013 → Aug 2015 | chronic hepatitis C virus infection | Beijing Kawin Technology Share-Holding Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-IFN-SA | “PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.” NCT01605513 ↗ |
| Known as | 171Arg126Asp171IFN | “PEG-IFN-SA is reorganization, unnatural existence and a new type of interferon (171Arg126Asp171IFN) after modification.” NCT01605513 ↗ |
| Known as | Pegylated Recombinant Consensus Interferon Variant Solution for Injection | “This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for...” NCT01908335 ↗1“This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA)...” NCT01903278 ↗ |
| Modality | Protein / enzyme biologic | “PEG-IFN-SA is a new recombinant interferon variant.” NCT01605513 ↗ |
| Route | Subcutaneous | “PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.” NCT01605513 ↗ |